Biofrontera Inc.

BFRI Healthcare Drug Manufacturers Specialty & Generic

Biofrontera Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.7 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.9%, EPS grew 91.2%, free cash flow grew 45.6% and total debt rose 6.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

0.82 0.03 −3.53%
Market cap
$12.6M
P/E
0.0×
Fwd P/E
−4.1×
Dividend yield
—
F-score
3/9
Altman Z
−5.67
Beneish M
0.02
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 3 4 4
ROE
(1,191.73%) (141.30%) (339.04%) (988.35%)
ROA
(103.57%) (41.59%) (53.58%) (28.80%)
ROIC
0.00% (81.82%) (155.74%) (69.45%)
Return on Tangible Assets
(934.68%) (126.24%) (251.30%) (157.82%)
Average Days of Receivables
29.41 63.81 32.77 43.83
Free Cash Flow per Share
(1.11) (1.31) (0.80) (0.61)
Free Cash Flow
(12.01) (13.36) (9.32) (7.93)
Other line items

Show all line items

Columns are period end dates